corticosteroids Flashcards

1
Q

Corticosteroids Drug Names

10 of them

A
  1. ) Hydrocortisone
  2. ) Prednisone
  3. ) Methylprednisolone
  4. ) Triamcinolone
  5. ) Dexamethasone
  6. ) Metyrapone
  7. ) Ketoconazole
  8. ) Fludrocortisone
  9. ) Spironolactone
  10. ) Cosyntropin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Short-to-medium- acting Glucocorticoids Drug Names

3 of them

A
  1. ) Hydrocortisone
  2. ) Prednisone
  3. ) Methylprednisolone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Intermediate-acting Glucocorticoids Drug Names

1 of them

A

1.) Triamcinolone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Long-acting Glucocorticoids Drug Names

1 of them

A

1.) Dexamethasone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Glucocorticoid synthesis inhibitor and antagonists Drug Names
(2 of them)

A
  1. ) Metyrapone
  2. ) Ketoconazole

Note that these are anti-fungal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Mineralocorticoids agonists Drug Names

1 of them

A

1.) Fludrocortisone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Glucocorticoid and Mineralocorticoid antagonists Drug Names

2 of them

A
  1. ) Metyrapone

2. ) Spironolactone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Glucocorticoid, mineralocorticoid, androgen, progesterone and estrogen agonist Drug Names
(1 of them)

A

1.) Cosyntropin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Regulation of Adrenocortical Hormone Secretion

A

The secretion of adrenocortical steroids is controlled by the pituitary release of corticotropin(ACTH). In the pituitary: ACTH synthesized from proopiomelanocortin (POMC). ACTH production is stimulated by corticotropin-releasing hormone (CRH), a peptide synthesized in the hypothalamus. Blood CRH and ACTH concentrations peak between 4 AM and 8 AM, and are lowest in the late evening or early sleep period. ACTH’s actions are mediated by the melanocortin receptor 2 (MC2R), a G protein-coupled
receptor found in the adrenal cortex, and results in adrenal cortex secretion of glucocorticoids, mineralocorticoids and androgen precursors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Aldosterone biosynthesis

A

A 3-beta-hydroxysteroid dehydrogenase, associated with the smooth endoplasmic reticulum catalyzes the conversion of pregnenolone to progesterone. CYP21A2 (21-hydroxylase, P450c21) then catalyze hydroxylations on C21 on progesterone to 11-deoxycorticosterone, which is then metabolized by CYP11B1 (11-beta-hydroxylase, p450c11) to corticosterone, a precursor of aldosterone. (See Figure 6)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Cortisol biosynthesis

A
involves CYP17 (17-alpha-hydroxylase, P450c17) that catalyzes hydroxylation at C17 on pregnenolone to 17-hydroxy-pregnenolone. A 3 betahydroxysteroid
dehydrogenase (associated with the smooth endoplasmic reticulum) catalyzes the conversion of 17-hydroxy-pregnenolone to 17-hydroxy-progesterone. Then CYP21A2 (21-hydroxylase, P450c21) catalyzes hydroxylations on C21 on 17-hydroxy- L25-L26-4
progesterone to 11-β-deoxycortisol, which is finally metabolized by CYP11B1 (11-betahydroxylase, p450c11) to cortisol or hydrocortisone. (See Figure 6)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Most endogenous cortisol is metabolized in the______ which is responsible for converting_____ to ______ as well as _____ to ______

A

Most endogenous cortisol is metabolized in the liver which is responsible for converting
inactive steroids to active metabolites as well as deactivating active steroids to inactive metabolites.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Most endogenous cortisol is metabolized in the______ which is responsible for converting_____ to ______ as well as _____ to ______

A
  • liver
  • inactive steroids to active metabolites as well as deactivating active steroids to less active or inactive metabolites.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Cortisol’s (10-20 mg synthesized daily in a normal adult in the absence of
stress) rate of production follows _________ governed by ACTH, peaking early morning and after meals. (See Figure 7)

A

circadian rhythm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cortisol’s (10-20 mg synthesized daily in a normal adult in the absence of
stress) rate of production follows _________ governed by _______, peaking ______ and _______
(See Figure 7)

A
  • circadian rhythm
  • ACTH
  • early morning
  • after meals.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

More than 90 % of cortisol circulates bound to ____________, a α2-globulin synthesized by liver. (See Figure 8)

A

-corticosteroid-binding globulin

CBG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

CBG levels may rise with_______, ______, and _______

A

-pregnancy, estrogen administration, and hyperthyroidism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

_______ has low affinity for cortisol, so _____-bound cortisol is considered free
cortisol.

A

Albumin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

The half-life of cortisol is_____

A

70-120 min in circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Glucocorticoids exert two types of negative feedback control on ACTH secretion, which
differ in the time required for their inhibitory effects. The _________ acts almost immediately and is responsible for normal minute-to-minute physiologic control. The_________ suppresses basal CRH and ACTH secretion when pharmacologic doses of glucocorticoids are administered. The amount of ACTH secreted at any time is
influenced by the _______ and ________ from circulating
glucocorticoids. (See Figure 1)

A
  • fast feedback system
  • delayed feedback system
  • integration of CRH stimulation
  • negative feedback
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Mineralocorticoid secretion regulation appears more complex. The ________ responds to electrolyte and volume changes by increasing or decreasing __________. ACTH also stimulates aldosterone secretion, but the effect is attenuated within 24 hours and there is ___________________. Aldosterone exhibits a slight_________ and serum concentrations tend to peak in the morning.

A
-renin-angiotensin
system
-aldosterone secretion
-no significant feedback effect on ACTH production
-circadian rhythmicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Steroids are very ____ soluble

A

lipid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Molecular mechanism of action of adrenocortical hormones (just read over)

A

1.) Mechanism of action is mediated by either the glucocorticoid receptors or
mineralocorticoid receptors.

2.) Two genes for the corticoid receptor have been identified (a) the glucocorticoid receptor,
and (b) the mineralocorticoid receptor.

  1. ) When not bound to a glucocorticoid, the receptor remains in the cytoplasm, in complexes with heat shock proteins (Hsp). (See Figure 9 & 10)
  2. ) 2 molecules of Hsp90 dissociate from the receptor in the presence of the glucocorticoid.

5.) Ligand-bound receptor complex is transported into the nucleus, where it interacts with
glucocorticoid receptor elements (GREs) in the promoters of responsive genes.
L25-L26-5

6.) Receptor interaction with promoter of target genes regulates their transcription: either promoting or inhibiting specific mRNAs.

7.) Besides GREs, the corticosteroid-bound complex influences function of other
transcriptions factors which regulate growth factors, proinflammatory cytokines, and
mediate anti-growth, anti-inflammatory, immunosuppressive effects of glucocorticoids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

The glucocorticoids influence_____ cells in the body, and thus have _______ effects

A
  • most

- widespread

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Glucocorticoids affect _______, ______, and _______ metabolism. In contrast, mineralocorticoids have ______ on intermediary metabolism. These responses are critical survival responses to _________.
(See Figure 11)

A
  • carbohydrate, protein, and fat
  • little effect
  • starvation and severe stress.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

In general, glucocorticoids enhance ______ and _________

A

glucose production and insulin release.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

_______ stimulate hepatic gluconeogenesis

A

Glucocorticoids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Glucocorticoids increase_______ and release of amino acids from peripheral and______

A
  • proteolysis

- intestinal tissues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Glucocorticoids enhance______ and_____ , with increased release of
fatty acids and glycerol into the circulation and______.

A
  • fatty acid mobilization and lipolysis

- hepatic cholesterol synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Net result of intermediary metabolism of glucocorticoids: maintain an adequate_____

A

glucose supply to the brain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Effects of adrenal corticosteroids on water and electrolyte balance

A

Exerted by aldosterone, through control of renal excretion of cations. (See Figure 12). Mineralocorticoids promote reabsorption of small but significant percentage of sodium in renal distal tubules. Renal excretion of potassium and hydrogen ions is enhanced.
(Na absorbed and K and H ions excreted)

32
Q

Glucocorticoid and Mineralocorticoid impact on Cardiovascular and blood cells

A

Both glucocorticoids and mineralocorticoids are important for support of normal cardiovascular structure and function.

Mineralocorticoids help maintain normal blood volume by sodium retention.

Glucocorticoids increase plasma hemoglobin concentration, the number of erythrocytes and polymorphonuclear leukocytes (neutrophils) in the blood, and elevate the total white
blood cell count.

Glucocorticoids decrease the number of circulating eosinophils, basophils, monocytes, and lymphocytes.

33
Q

Corticosteroid impact on Cardiovascular and blood cells

A

Both glucocorticoids and mineralocorticoids are important for support of normal cardiovascular structure and function.

Mineralocorticoids help maintain normal blood volume by sodium retention.

Glucocorticoids increase plasma hemoglobin concentration, the number of erythrocytes and polymorphonuclear leukocytes (neutrophils) in the blood, and elevate the total white
blood cell count.

Glucocorticoids decrease the number of circulating eosinophils, basophils, monocytes, and lymphocytes.

34
Q

Corticosteroid impact on Immune system

A

Glucocorticoids Inhibit prostaglandin and leukotriene production by inducing production of lipocortin (annexins) that inhibit phospholipase A2. (See Figure 13)

Glucocorticoids reduce manifestations of inflammation.

Glucocorticoids suppress release of inflammatory cytokines and chemokines.

35
Q

Corticosteroid impact on Central Nervous System (CNS)

A

The role of corticosteroids in the CNS is poorly defined.

Corticosteroids can readily enter the brain and can influence mood, sleep patterns, and
electroencephalographic (EEG) activity.

Adrenal insufficiency is associated with changes in mood (irritability and depression).

Mainly know that they cross the BBB

36
Q

Corticosteroid impact on Skeletal muscle

A

Corticosteroids are required to maintain skeletal muscular strength.

However, large amounts of glucocorticoids stimulate proteolysis in myocytes, pain, and muscle weakness.

37
Q

Corticosteroid impact on

Stress

A

Increased glucocorticoid secretion in response to stressful stimuli is protective, in fact, cortisol secretion increases with stress.

38
Q

Nonendocrine use of glucocorticoids can be used for ______, ______, and _____ disorders

A

inflammatory, allergic and immunological disorders

39
Q

Natural and synthetic glucocorticoids can be used for both_____ and______
disorders.

A
  • endocrine

- nonendocrine

40
Q

Nonendocrine use of glucocorticoids: Allergic Disorders

A

Systemic administration of glucocorticoids relieves symptoms in allergic diseases. Eg: seasonal allergic rhinitis (hay fever); reactions to drugs; allergic dermatoses.

Inhaled steroids are used as first-line therapy for mild to moderate asthma.

For anaphylactic reactions, steroids are used as adjuncts to epinephrine and cardiorespiratory support (Review immunopharmacology lecture, Drug Allergy).

Treatment: may include:

  • prednisone
  • methylprednisolone
  • triamcinolone
  • dexamethasone.
41
Q

Nonendocrine use of glucocorticoids:

Cerebral Edema

A

Glucocorticoids appear to be effective in vasogenic type edema, as observed with brain
tumors (metastases and glioblastomas).

Edemas from brain abscesses respond well to glucocorticoids; edema produced by closed
head injury is less responsive.

Treatment may include:
-prednisone

42
Q

Nonendocrine use of glucocorticoids:

Bacterial meningitis

A

* Gram (-) bacteria causes this*

Approximately 15,000 infants and children develop meningitis each year, and although antimicrobial therapy has advanced, up to 10% of cases are fatal.

The cytokines TNF-α and interleukin 1-β play a role in meningeal inflammation, which may cause increased cerebral pressure, blood flow reduction and ischemia.

LPS (lipopolysaccharide or endotoxin) is released when microbial cells lyse after antibiotic treatment, and may trigger cytokine release.

Anti-inflammatory effects of glucocorticoids in meningitis include a reduction of brain
edema, and reductions of TNF-α, interleukin-1, and prostaglandin E2 in cerebrospinal fluid.

Glucocorticoids are beneficial as adjuncts to antimicrobial therapy in the treatment of
acute, nontuberculous bacterial meningitis.

Treatment may include:
-dexamethasone.

43
Q

Nonendocrine use of glucocorticoids:

Collagen disorders

A

High doses of glucocorticoids are beneficial for acute exacerbations.

Systemic lupus erythematosus may be treated with glucocorticoids.

Glucocorticoids, with azathioprine or cyclophosphamide may slow progression of renal
failure in lupus nephritis.

Glucocorticoids are the agents of choice for polymyositis and dermatomyositis, (idiopathic
inflammatory myopathies) caused by autoimmune response.

Polymyalgia rheumatica (inflammatory rheumatic condition) occurs in individuals over 60 years and usually responds well to high-dose corticosteroid therapy.
L25-L26-8

Treatments may include:

  • prednisone,
  • methylprednisolone,
  • triamcinolone,
  • dexamethasone.
44
Q

Nonendocrine use of glucocorticoids:

Hematological disorders

A

Glucocorticoids inhibit phagocytosis of antibody-associated platelets, thus resulting in an increased platelet life span.

Treatment may include:

  • prednisone
  • triamcinolone
  • dexamethasone.
45
Q

Nonendocrine use of glucocorticoids:

Hepatic disease

A

subacute hepatic necrosis (prednisolone)

autoimmune chronic hepatitis.

Concomitant use of azathioprine allows for a reduction of the glucocorticoid dose.

46
Q

Nonendocrine use of glucocorticoids:

Renal Disease

A

Glucocorticoids are used to treat the most common subtype of idiopathic nephrotic syndrome in patients less than 16 years.

Treatment consists of:

-methylprednisolone, with 80-90% of children responding within 4-8 weeks.

47
Q

Nonendocrine use of glucocorticoids:

Respiratory disorders

A

Respiratory distress syndrome is a significant cause of death in premature neonates.
Antenatal administration of glucocorticoids reduces the incidence, severity and mortality rate.

Treatment:
-i.m. dexamethasone

Optimal benefit begins 24 hours after initiation of therapy
and lasts seven days.

Significant benefit has been observed in infants at 26-34 weeks gestation when delivery occurred at least 24 h after initiation of therapy.

48
Q

Adverse effects of glucocorticoids General

A

“Glucocorticoids cannot be given chronically without the risk of adverse effects”.

The adverse effects of corticosteroids usually correlate with dose, frequency and route of administration,
duration of the therapy, age and condition of the patient, and underlying disease.

The risk versus benefits for each patient should be considered before treatment is initiated with a corticosteroid.

Adverse effects range from not serious but displeasing, eg. Cushingoid appearance, to those that could be life-threatening, eg. serious infections.

Unfortunately some of the adverse effects may be
asymptomatic (eg. vertebral osteoporosis, cataracts) until manifestations develop that require medical treatment (eg. acute vertebral collapse, cataracts requiring surgery). (See Figure 14)

49
Q

Adverse effects of glucocorticoids:

G.I reactions

A

Decrease the protection provided by the gastric mucus barrier, and may increase gastric acid and pepsinogen production.

Gastric ulcers: glucocorticoids may produce peptic ulcers in patients with glucocorticoid treated rheumatoid arthritis.

Synergism with NSAIDS: may lead to an increase GI events.

Bleeding: glucocorticoids may mask symptoms of peptic ulcers, so that perforation or
hemorrhage may occur without pain, therefore periodic examination of stools for occult blood is required.

If an ulcer occurs, corticosteroids should be discontinued slowly, and antiulcer therapy should be prescribed

50
Q

Adverse effects of glucocorticoids:

Edema

A

Glucocorticoids may cause fluid retention (uptake of Na) in patients with heart or kidney disease.

Caution: treatment of patients with cardiovascular or renal disease with large doses of
corticosteroids, because fluid retention may be dangerous.

To treat edema, it is best to restrict dietary sodium at therapy initiation. If it persists,
sodium intake should be reduced further and patients should receive glucocorticoids with less mineralocorticoid activity.

51
Q

Adverse effects of glucocorticoids:

Carbohydrate & lipid metabolism

A
Glucocorticoids treatment may result in hyperglycemia. Plasma glucose concentrations
increase 10-20% by 
(a) enhanced gluconeogenesis
                   AND 
  (b)  decreased cellular 
        sensitivity to insulin.

Glucocorticoids can aggravate diabetes.

Patients with normal pancreatic insulin production and response are not affected.

Serum triglyceride concentrations are frequently elevated.

Glucocorticoids may increase the risk for atherosclerotic vascular disease, mediated by
elevated lipoprotein levels.

52
Q

Adverse effects of glucocorticoids:
Hypokalemia
(Low K)

A

Administration of high doses of glucocorticoids may cause hypokalemia and metabolic
alkalosis.

Significant hypokalemia is uncommon with routine use of exogenous glucocorticoid use.

Severe hypokalemia may cause asthenia, paralysis or arrhythmias that could proceed to cardiac arrest.

Incidence of hypokalemia is related to the mineralocorticoid activity of a specific glucocorticoid.

Hypokalemia can be avoided if patients:

(a) restrict dietary sodium, and consume potassium-rich foods (eg. spinach, raisins, orange juice, cantaloupe, bananas, etc),
(b) take oral potassium supplements
(c) use a steroid with minimal mineralocorticoid activity.

53
Q

Adverse effects of glucocorticoids:
Hyphosphatemia
(Low Phosphate)

A

Administration of corticosteroids will rarely result in extremely low levels of phosphate, which could result in severe muscle weakness, cardiac dysfunction, and hemolysis.

Serum phosphate levels: should be monitored in patients receiving long-term, high-dose therapy.

It is helpful to ingest milk or equivalent dairy products.

Potassium or sodium phosphate preparations are required for severely affected patients

54
Q

Adverse effects of glucocorticoids:

Osteonecrosis

A

Corticosteroids may cause osteonecrosis. Most commonly: femoral head, but also may involve the head of the humerus, femoral condyles, tibial plateau, talus, and capitulum.

Mechanisms hypothesized include: 
-fat embolism 
-hypercoagulability
-increased intraosseous 
 pressure
-swelling of fat cells.
First symptoms: 
-joint pain
-stiffness 
(Noted 12-24 months after the first treatment
with a corticosteroid.)

Osteonecrosis is commonly associated with:

(a) prolonged corticosteroid treatment
(b) high doses of glucocorticoids.

55
Q

Adverse effects of glucocorticoids:

Negative N balance

A

negative nitrogen balance results from excessive breakdown of protein by
glucocorticoids.

This process may be modified by patients consuming a high-protein diet.

56
Q

Adverse effects of glucocorticoids:

CNS edema

A

Corticosteroids used in high doses may cause behavioral and personality changes.
Euphoria is a common clinical observation.

Other CNS signs:

  • insomnia
  • increased appetite
  • nervousness
  • irritability
  • sleep disturbances.

Also reported:

  • psychotic episodes
  • manic-depressive
  • paranoid states
  • psychoses

Symptoms which develop within days to two weeks after therapy initiation may disappear completely or partly on reduction of dosage.

57
Q

Adverse effects of glucocorticoids:

Growth suppression

A

Just know that this can happen in children receiving long-term, daily glucocorticoid therapy.

58
Q

Adverse effects of glucocorticoids:

Myopathy

A

Due to Negative N Balance

Glucocorticoid use in pharmacologic doses causes protein catabolism, myopathy (muscle weakness) and loss of muscle mass.

Myopathy develops slowly, involving the musculature of the upper and lower extremities,

Myopathy is REVERSIBLE, requires corticosteroid dosage reduction, and time (several months).

Myopathy is associated with 9α-fluorinated steroids, eg. triamcinolone

Myopathy rarely occurs in patients receiving less than 30mg daily of prednisone or
equivalent dose.

59
Q

Adverse effects of glucocorticoids:

Skin and Soft Tissues

A

Cushingoid features:

  • truncal obesity
  • buffalo hump
  • moon face
  • weight gain

May be observed in patients receiving glucocorticoids above physiologic range, i.e. greater than 7.5 mg/day prednisone or equivalent.

60
Q

Adverse effects of glucocorticoids:

Skin and Soft Tissues

A

Due to Negative N Balance

Cushingoid features:

  • truncal obesity
  • buffalo hump
  • moon face
  • weight gain

May be observed in patients receiving glucocorticoids above physiologic range, i.e. greater than 7.5 mg/day prednisone or equivalent.

61
Q

Adverse effects of glucocorticoids:

Ocular effects

A

INCREASED IOP

Use of glucocorticoids may enhance development of secondary ocular infections by fungi or viruses. (Because of immunosuppression of patients)

EXAM QUESTION

62
Q

Adverse effects of glucocorticoids:

Infections

A

Prolonged use of pharmacologic doses of glucocorticoids decreases resistance to infection, because they inhibit the mechanisms that are involved in inflammation.

Patients treated with glucocorticoids are susceptible to bacterial, viral, fungal and parasitic infections.

Alternate-day therapy (ADT) appears to result in fewer infections, because the
immunologic defenses remain intact. The risk of infections can be decreased by using short-acting preparations (eg. prednisone).

Reactivation of latent tuberculosis may result in patients receiving glucocorticoids.

63
Q

Adverse effects of glucocorticoids:

HPA suppression

A

Exogenous administration of glucocorticoids will result in suppression of the hypothalamic-pituitary-adrenal (HPA) axis through negative feedback.

HPA suppression is proportional to: dose and activity of glucocorticoid, biological half-life,
and duration of treatment.

Significant adrenal suppression may occur one week after a large glucocorticoid dose is
used.

In general, 5 mg of prednisone daily or the equivalent causes little suppression.

Divided glucocorticoid doses (3 or 4 times a day) are more suppressive than a single dose.

Glucocorticoids administered just before or at bedtime are more suppressive than those
given earlier in the day.

64
Q

Adverse effects of glucocorticoids:

Pregnancy and lactation

A

Studies with perfused human placenta have shown that cortisol, prednisolone,
prednisone and dexamethasone are metabolized prior to crossing the placenta and entering into the fetus.

Large pharmacologic doses of glucocorticoids used during pregnancy may result in fetal
adrenal hypoplasia.

Infants born to mothers receiving high doses of glucocorticoids should be monitored for signs of hypoadrenalism.

Glucocorticoid use in pregnancy may increase risk of cleft palate in offspring.

Glucocorticoids are classified as FDA Pregnancy Category C.

65
Q

Mineralocorticoids:

Aldosterone biosynthesis.

A

Aldosterone biosynthesis requires the conversion of pregnenolone to progesterone, hydroxylation on C21 of progesterone to 11-deoxycorticosterone, which is then metabolized by to corticosterone, a precursor of aldosterone (See Figure 6).

66
Q

Mineralocorticoids: Physiologic and pharmacologic effects

A

Aldosterone promotes reabsorption of sodium in the distal part of the distal convoluted tubule (cortical collecting renal tubules). (See Figure 12)

Reabsorption of sodium is coupled to potassium and hydrogen ion excretion.

Aldosterone binds to the cytoplasmatic mineralocorticoid receptor of a target cell, and then the aldosterone-receptor complex activates a signal transduction pathway. (See Figure 15)

Major effect of activation of the aldosterone-receptor complex:

  • Increased expression of Na+/K+ ATPase
  • Epithelial sodium channel.

Excessive levels of aldosterone may lead to:

  • hypokalemia
  • metabolic alkalosis
  • increase in plasma volume
  • hypertension.
67
Q

Mineralocorticoids:

Drug selection

A
  • **Fludrocortisone: Potent steroid with both glucocorticoid and mineralocorticoid
    activity. (See Chart)

Most widely used mineralocorticoid.

Used to treat:
-adrenocortical insufficiency
associated with
mineralocorticoid deficiency.

68
Q

Use of Corticosteroids for endocrine disorders

A

***HYPERsecretion of adrenocortical hormones. Upon ACTH release from the pituitary gland, cortisol is produced by the adrenal gland. (See Figure 16)

Cushing’s syndrome: also know as hypercortisolism or hyperadrenocorticism, is an
endocrine disorder caused by supraphysiologic levels of cortisol. High cortisol in the
blood may be:
-ACTH-dependent
or
-ACTH-independent.
(See Figure 18).

***-ACTH-dependent cortisol hypersecretion:
May occur if there is secretion of ACTH by a pituitary adenoma. This is known as Cushing’s disease. Cushing’s disease specifically refers to a tumor in the pituitary
gland releasing large amounts of ACTH that stimulate excessive release of cortisol
from the adrenal gland. IMPORTANT: in Cushing’s disease, the pituitary gland does not respond to negative feedback to high levels of cortisol, and continues to
produce ACTH. (See Figures 17 and 19) ACTH-dependent cortisol hypersecretion in ectopic ACTH syndrome (12% of
Cushing’s syndrome patients). Patients present with a bilateral adrenal hyperplasia
L25-L26-15 caused by ACTH-secreting tumors such as lung carcinoma, thyroid, esophagus, islet cell, ovary, breast or prostate, bronchial adenomas, and carcinoid tumors.

***ACTH- independent cortisol hypersecretion:
Occurs in 18% of Cushing’s syndrome patients. Patients present with benign adrenal adenomas or adrenocortical
carcinomas.

69
Q

Use of Corticosteroids for endocrine disorders:

Treatment

A

Ketoconozale SHUTS EVERYTHING DOWN

Cortisol release can be diminished by administration of drugs that inhibit the enzymes involved in the synthesis of cortisol.

-Metyrapone (Metopirone) inhibits CYP11B1 (11 β-hydroxylase) which is the
enzyme that converts 11-deoxycortisol to cortisol. (See Figure 6) As a result of
metyrapone administration there is an inhibition of both cortisol and aldosterone.

Ketoconozale (Nizoral) inhibits CYP17 (17 α-hydroxylase) and at higher concentrations CYP11A1, enzyme involved in the conversion of cholesterol to pregnenolone, effectively blocking all steroid biosynthesis. It is the most effective inhibitor in Cushing’s disease. It is also an antifungal agent

Ketoconazole is the first drug used, it acts quickly to inhibit cortisol synthesis. If it
does not control cortisol secretion, then Metyrapone is added. The drugs tend to
act synergistically

70
Q

HYPERaldosteronism or Conn’s syndrome

A

Results from increased plasma aldosterone

Treatment:
-Adrenal adenomas or carcinomas are removed by surgery

-Spironolactone (Aldactone) is used to normalize potassium concentrations before
surgery, and with a low-sodium diet.

-Postoperative glucocorticoid and mineralocorticoid replacement therapy has
significantly increased survival.

71
Q

HYPOsecretion of Adrenocortical hormone: Hypoadrenalism

A

Defects in the HPA axis will result in a decrease in corticosteroid release.

A deficiency in adrenal function can result from:

  • Destruction of the adrenal glands
  • Inadequate secretion of ACTH or CRH
  • Congenital defects in steroidogenesis
72
Q

HYPOsecretion of Adrenocortical hormone:

Primary adrenocortical insufficiency , OR Addison’s disease

A

Autoimmune disease, characterized by antibodies against adrenal antigens

73
Q

HYPOsecretion of Adrenocortical hormone:

Secondary adrenocortical insufficiency

A

ACTH deficiency which can be caused by:

-Surgical ablation of the
pituitary

-Pituitary disease

OR

-Pituitary suppression after prolonged administration of glucocorticoids in pharmacological doses.

74
Q

HYPOsecretion of Adrenocortical hormone:

Diagnosis

A

***Synthetic ACTH (Cosyntropin) can be used to test adrenal function ( See Figure 22 and Chart).

***In normal individuals, after a single iv injection of cosyntropin, plasma cortisol and aldosterone concentrations peak 30-60 min later. A subnormal response confirms the diagnosis of adrenal insufficiency.

75
Q

HYPOsecretion of Adrenocortical hormone:

Treatment

A

Replacement therapy for adrenocortical insufficiency should simulate normal
glucocorticoid secretion patterns.

Hydrocortisone and cortisone are preferred for initial treatment, because they
have strong glucocorticoid and moderate mineralocorticoid properties.

The potent mineralocorticoid fludrocortisone is added when the dose of hydrocortisone is reduced.

Prednisone and prednisolone may be used, but lack of mineralocorticoid activity
in dosages appropriate for replacement therapy requires concomitant use of fludrocortisone.